Arena Pharmaceuticals Stock Price - ARNA

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 46.90 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Arena Pharmaceuticals Inc ARNA NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.59 1.27% 46.90 46.95 45.68 46.44 46.31 18:00:14
Bid Price Ask Price Spread Spread % News
46.72 50.00 3.28 6.56% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,942 390,343 $ 46.29 $ 18,069,853 322,114 34.50 - 64.48
Last Trade Time Type Quantity Stock Price Currency
17:56:16 formt 8,209 $ 46.90 USD

Arena Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.35B 50.11M $ -29.40M -0.66 4.30 47.54M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Arena Pharmaceuticals News

Loading Messages....

Latest ARNA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARNA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week45.9247.4344.65545.76365,2120.982.13%
1 Month48.3650.3143.08547.46328,479-1.46-3.02%
3 Months53.9454.2543.08548.56356,407-7.04-13.05%
6 Months53.9364.4843.08554.04426,139-7.03-13.04%
1 Year39.3464.4834.5049.52459,3967.5619.22%
3 Years15.7064.4811.3028.65907,27631.20198.73%
5 Years42.4064.4811.3033.401,722,1974.5010.61%

Arena Pharmaceuticals Description

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.